This study confirms that SGLT2 inhibitor therapy leads to significant reductions in cardiovascular risk scores, metabolic dysregulation, and laboratory abnormalities in patients with T2DM. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.